Acella Recalls Subpotent NP Thyroid 15 Tablets Nationwide
Acella Pharmaceuticals is recalling NP Thyroid 15 tablets because they contain less active ingredient than labeled. The recall covers bottles distributed nationwide.
The agency’s classification
FDA (Drugs): Class I
Class I is a situation in which there is a reasonable probability that the use of or exposure to a violative product will cause serious adverse health consequences or death.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 5/5 (Critical).
Highest-severity recall. The hazard can cause serious injury or death. Stop using the product now and follow the agency's instructions.
Our severity reasoning: The FDA classified this recall as Class I, which per the rubric mandates a severity score of 5 (Critical) regardless of other factors.
Plain-English summary
Acella Pharmaceuticals, LLC is voluntarily recalling NP Thyroid 15 Thyroid Tablets, USP. The recall was initiated on April 29, 2021, because the tablets were found to be subpotent, meaning they contain less of the active ingredients levothyroxine and liothyronine than stated on the label.
The affected product is packaged in 100-count bottles (NDC 42192-327-01) and 7-count bottles (NDC 42192-327-07). The recall includes specific lots with expiration dates ranging from April 30, 2021, to March 31, 2022. A total of 66,155 bottles of the 100-count size and 26,212 bottles of the 7-count size are involved.
The product was distributed nationwide within the United States, including Puerto Rico. The FDA classified this as a Class I recall, which is the most serious type, indicating a reasonable probability that use of the product could cause serious adverse health consequences or death. Patients should stop using the recalled product and consult their healthcare provider for alternative treatment.
The recalled product
- Product
- NP THYROID 15 (LEVOTHYROXINE, LIOTHYRONINE)
- Brand
- NP THYROID 15
- Manufacturer
- Acella Pharmaceuticals, LLC
- Category
- Drug — Thyroid Hormone
- Hazard
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (5)
- Lots: a) M327D20-1
- M327D20-3 Exp. 03/31/2022
- M327H19-3A Exp. 07/31/2021
- M327L19-1 Exp. 04/30/2021
- b) M327D20-1 Exp. 03/31/2022
UPCs (4)
- 0342192329102
- 0342192330108
- 0342192327016
- 0342192328013
Distribution
Part of a larger recall action
This product is one of 5 recalled by Acella Pharmaceuticals, LLC under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 5 products in this recall →Related recalls
Same brand · NP THYROID 15
- CriticalAcella Recalls Subpotent NP Thyroid 15 Prescription Tablets
FDA (Drugs) · 2021-06-02
- SevereAcella Recalls Subpotent NP Thyroid 15 Tablets Nationwide
FDA (Drugs) · 2021-06-02
- CriticalAcella Pharmaceuticals Recalls Subpotent NP Thyroid 15 Prescription Tablets
FDA (Drugs) · 2021-06-02
- CriticalAcella Recalls Subpotent NP Thyroid 15 Tablets Nationwide
FDA (Drugs) · 2021-06-02
- SevereAcella Recalls NP Thyroid 15 Tablets Due to Subpotent Levothyroxine Levels
FDA (Drugs) · 2020-10-28
Same manufacturer · Acella Pharmaceuticals, LLC
See all →- SevereNaproxen Oral Suspension Recalled for Lead and Lithium Contamination
FDA (Drugs) · 2026-05-13
- ModerateDoxycycline hyclate tablets recalled after stability testing failed dissolution specifications
FDA (Drugs) · 2025-10-15
- ModeratePrescription skin cleanser recalled nationwide due to subpotency
FDA (Drugs) · 2024-05-15
- ModerateAcella Recalls Sodium Sulfacetamide Cleansing Pads for Subpotency
FDA (Drugs) · 2022-12-07
- LowPhenytoin Sodium Injection Recalled for Missing Barcode on Vial Label
FDA (Drugs) · 2022-11-30
Same hazard · subpotent drug
See all →- LowImprimisRx Recalls Subpotent Povidone Iodine and Proparacaine Ophthalmic Solution
FDA (Drugs) · 2026-09-16
- HighAccord Healthcare Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
- SevereAccord Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
- HighAccord Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
- HighAccord Healthcare Recalls Subpotent Levothyroxine Sodium Tablets
FDA (Drugs) · 2026-09-02
Similar recalls
- CriticalAcella Recalls NP Thyroid 15 Tablets Due to Subpotent Levothyroxine
FDA (Drugs) · 2020-10-28
- SevereAcella Recalls NP Thyroid 15 Tablets Due to Subpotent Levothyroxine Levels
FDA (Drugs) · 2020-10-28
- CriticalAcella Recalls NP Thyroid 15 Tablets Due to Superpotent Drug Risk
FDA (Drugs) · 2020-06-10
- CriticalAcella Recalls Superpotent NP Thyroid 15 Thyroid Tablets Nationwide
FDA (Drugs) · 2020-06-10
- CriticalAcella Recalls Superpotent NP Thyroid 15 Tablets Nationwide
FDA (Drugs) · 2020-06-10
- CriticalRLC Labs Recalls Subpotent Nature Throid Thyroid Medication
FDA (Drugs) · 2020-09-23